Treatment of Migraine and Cluster Headache with Calcium Antagonists

  • J. S. Meyer
  • J. Lotfi
  • M. Kobari
Conference paper


A number of pharmacological agents have recently become available that are capable of limiting or blocking calcium passage through cellular membrane channels. These drugs are termed calcium antagonists or calcium channel or calcium entry blockers. Cell membranes of smooth muscle and nerve cells have several different calcium channels which may be selectively altered by calcium channel blockers [28, 29]. Since the cellular entry of calcium initiates contraction of vascular smooth muscle, calcium channel blockers exert both antispasmodic and slight vasodilator actions [6]. Calcium channels are susceptible to ischemia resulting in calcium entry with intracellular “overload”, which may be responsible for cell damage and eventually cell death [7, 26]. Calcium antagonists also exert protective actions against ischemic and anoxic damage to both nerve cells and smooth muscle.


Calcium Channel Blocker Calcium Antagonist Cluster Headache Migraine Attack Migraine Prophylaxis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ad Hoc Committee on Classification of Headache (1962) Classification of headache. JAMA 179:717–718CrossRefGoogle Scholar
  2. 2.
    Amery WK, Caers LI, Aerts TJL (1985) Flunarizine, a calcium entry blocker in migraine prophylaxis. Headache 25:249–254PubMedCrossRefGoogle Scholar
  3. 3.
    Amery WK, Wauquier A, Van Nueten JM, DeClerck F, Van Reempts JV, Janssen PAJ (1981) The anti-migrainous pharmacology of flunarizine (R14950), a calcium antagonist. Drugs Exp Clin Res VII(1):1–10Google Scholar
  4. 4.
    Antman E, Muller J, Goldberg S et al. (1980) Nifedipine therapy for coronary-artery spasm. N Engl J Med 302:1269–1273PubMedCrossRefGoogle Scholar
  5. 5.
    Bussone G, Baldini S, D’Andréa G et al. (1987) Nimodipine vs flunarizine in common migraine. A controlled pilot trial. Headache 27:76–79PubMedCrossRefGoogle Scholar
  6. 6.
    Cauvin C, Loutzenhiser R, Van Breemen C (1983) Mechanism of calcium antagonist induced vasodilation. Ann Rev Pharmacol Toxicol 23:373–396CrossRefGoogle Scholar
  7. 7.
    Diamond S, Schenbaum H (1983) Flunarizine, a calcium channel blocker, in the prophylactic treatment of migraine. Headache 23:39–42PubMedCrossRefGoogle Scholar
  8. 8.
    Farber JL (1981) The role of calcium in cell death. Life Sci 29:1289–1295PubMedCrossRefGoogle Scholar
  9. 9.
    Flaim SF (1982) Comparative pharmacology of calcium blockers, based on studies of vascular smooth muscle. In: Flaim SF, Zolis R (eds) Calcium blockers: mechanism of action and clinical application. Urban & Schwarzenberg, Baltimore, pp 155–178Google Scholar
  10. 10.
    Fleckenstein A (1964) Die Bedeutung der energiereichen Phosphate für Kontraktiiitat und Tonus des Myokards. Verh Dtsch Ges Inn Med 70:81–89PubMedGoogle Scholar
  11. 11.
    Fleckenstein A (1977) Specific pharmacology of calcium in myocardia, cardiac pacemakers and vascular smooth muscle. Annu Rev Pharmacol Toxicol 17:149–166PubMedCrossRefGoogle Scholar
  12. 12.
    Fleckenstein A, Tritthart H, Fleckenstein B, Herbst A, Grun B (1969) A new group of competitive calcium antagonists (Iproveratril, D600, prenylaine) with highly potent inhibitory effect on excitation/conduction coupling in mammalian myocardium. Pflügers Arch 307:R25PubMedGoogle Scholar
  13. 13.
    Freedman SB, Dawson G, Villareal ML, Miller RJ (1984) Identification and characterization of voltage-sensitive calcium channels in neuronal clonal cell lines. J Neurosci 4:1453–1467PubMedGoogle Scholar
  14. 14.
    Gelmers HJ (1983) Nimodipine, a new calcium antagonist in the prophylactic treatment of migraine. Headache 23:106–109PubMedCrossRefGoogle Scholar
  15. 15.
    Havanka-Kanniaiken H, Hokkanen E, Myllyla VV (1985) Efficacy of nimodipine in the prophylaxis of migraine. Cephalalgia 5(1):39–43CrossRefGoogle Scholar
  16. 16.
    Havanka-Kanniaiken H, Myllyla VV, Hokkanen E (1982) Nimodipine in the prophylaxis of migraine, a double-blind study. Acta Neurol Scand 65(Suppl 90):77–78Google Scholar
  17. 17.
    Jonsdottir M, Meyer JS, Rogers RL (1987) Efficacy, side effects and tolerance compared during headache treatment with three different calcium blockers. Headache 27:364–369PubMedCrossRefGoogle Scholar
  18. 18.
    Kahan A, Weber S, Amor B, Guerin F, Degeorge M (1983) Nifedipine in the treatment of migraine in patients with Raynauds’ phenomenon (letter). N Eng J Med 308:1102–1103Google Scholar
  19. 19.
    Louis P (1981) A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache 21:235–239PubMedCrossRefGoogle Scholar
  20. 20.
    Louis P, Spierings ELH (1982) Comparison of flunarizine (Sibelium) and pizotifen (Sandomigran) in migraine treatment. Cephalalgia 2:197–203PubMedCrossRefGoogle Scholar
  21. 21.
    McGoon M, Vlietstra R, Holmes D, Osborn JE (1982) The clinical use of verapamil. Mayo Clin Proc 57:495–510PubMedGoogle Scholar
  22. 22.
    Markley HG, Cheronis JCD, Piepho RW (1984) Verapamil in prophylactic therapy of migraine. Neurology 34:963–976CrossRefGoogle Scholar
  23. 23.
    Meyer JS, Dowell R, Mathew N, Hardenberg J (1984) Clinical and hemodynamic treatment of vascular headaches with verapamil. Headache 24:313–321PubMedCrossRefGoogle Scholar
  24. 24.
    Meyer JS, Hardenberg J (1983) Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headaches. Headache 23:266–277PubMedCrossRefGoogle Scholar
  25. 25.
    Micieli G, Trucco M, Agostinis C, Mancuso A, Papalia F, Sinforiani E (1985) Nimodipine vs. pizotifen in common migraine. Results of double-blind cross-over trial. Cephalalgia 5(Suppl 3):532–533Google Scholar
  26. 26.
    Myrhed M, Wilholm B-E (1986) Nifedipine — a survey of side effects: four years’ reporting in Sweden. Acta Pharmacol Toxicol 133–136Google Scholar
  27. 27.
    Nattero G, Savi L, Delorenzo C (1985) Flunarizine in the treatment of headache with or without neurological symptoms. Cephalalgia 5(Suppl 2): 141–143PubMedGoogle Scholar
  28. 28.
    Peroutka CJ (1983) The pharmacology of calcium channel antagonists: a novel class of antimigraine agents? Headache 23:278–283PubMedCrossRefGoogle Scholar
  29. 29.
    Peroutka CJ, Banghart SB, Allen GS (1984) Relative potency and selectivity of calcium antagonists used in the treatment of migraine. Headache 24:55–58PubMedCrossRefGoogle Scholar
  30. 30.
    Riopelle RJ, McCans JL (1982) A pilot study of the calcium antagonist diltiazem in migraine syndrome prophylaxis. Can J Neurol Sci 9:269Google Scholar
  31. 31.
    Smith R, Schwartz A (1984) Diltiazem prophylaxis in refractory migraine (letter). N Engl J Med 310:1327–1328PubMedCrossRefGoogle Scholar
  32. 32.
    Solomon GD, Griffith Steel MC, Spaccavento LJ (1983) Verapamil prophylaxis of migraine. JAMA 250:250–252Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • J. S. Meyer
    • 1
  • J. Lotfi
    • 1
  • M. Kobari
    • 1
  1. 1.Cerebral Blood Flow LaboratoryVeterans Administration Medical CenterHoustonUSA

Personalised recommendations